The ACTR1B Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line. This heterogeneous pool carries targeted disruptions in the ACTR1B gene, enabling loss-of-function studies without clonal selection. The polyclonal format maintains genetic diversity and is well-suited for pooled functional screens and bulk biochemical assays where clonal variation may confound results.
AGS cells are an adherent epithelial cell line originally established from a primary gastric adenocarcinoma of a 54-year-old female patient. This model recapitulates key features of gastric cancer, including aberrant mucin secretion, disrupted epithelial barrier function, and deregulated signaling pathways. Widely used in gastrointestinal oncology, AGS cells provide a clinically relevant platform to study tumorigenesis, metastasis, and drug resistance.
ACTR1B encodes beta-centractin, an essential core subunit of the dynactin complex. Beta-centractin polymerizes into the Arp1 filament, which scaffolds dynactin assembly and mediates interaction with cytoplasmic dynein (DYNC1H1). The dynactin complex, comprising DCTN1, DCTN2, and DCTN3, is regulated by phosphorylation from CDK1 and PLK1, which control its mitotic functions. Adaptor proteins such as BICD2 link dynactin to specific cargoes, including RAB11A-positive recycling endosomes, to drive minus-end-directed transport along microtubules. Downstream, ACTR1B-dependent dynein activity is required for Golgi ribbon maintenance, lysosomal positioning, and mitotic spindle orientation. Disruption of ACTR1B is expected to perturb these fundamental processes, leading to organelle mislocalization and mitotic defects.
In the context of gastric adenocarcinoma, dynactin-mediated intracellular trafficking is critical for cancer cell proliferation, invasion, and survival. The ACTR1B knockout in AGS cells allows dissection of retrograde transport contributions to gastric cancer progression. Loss of beta-centractin function may impair autophagic flux and endolysosomal trafficking, pathways frequently co-opted by cancer cells. Moreover, mitotic spindle defects arising from dynactin disruption can induce chromosomal instability, a hallmark of malignancy. This model provides a unique opportunity to study the interplay between organelle dynamics and gastric adenocarcinoma aggressiveness, including the potential to uncover therapeutic vulnerabilities associated with dynein-dynactin inhibition.
Researchers can utilize the ACTR1B Knockout AGS Polyclonal Cells in diverse functional assays. Immunofluorescence microscopy enables visualization of Golgi fragmentation and lysosomal clustering, classical phenotypes of dynactin dysfunction. Live-cell imaging of vesicle trafficking permits real-time quantification of retrograde transport defects. Western blot analysis for ACTR1B and DCTN1 validates target disruption, while co-immunoprecipitation reveals compromised dynactin-dynein complex assembly. Additional applications include cell migration assays (wound healing or transwell), flow cytometric cell cycle analysis, and drug sensitivity screening to assess chemotherapeutic response. For further information or to design experiments with this product, please contact Ascent Research.
